Friday, November 30, 2012 (All day)

Burton-on-Trent, UK  – 30 November  2012 Clinigen Group plc, the global specialty pharmaceuticals and services business, has won the 2012 Bionow Award for Investment Deal of the Year following its admission to the London Stock Exchange’s Alternative Investment Market (AIM) on 25 September 

Clinigen Group was one of three companies shortlisted for the award, beating off competition from Cheshire-based businesses Biofortuna and F2G. 

The Bionow Awards, now in their 11th year, honour the best companies in the biomedical sector in the North of England. The Clinigen team were commended for their exceptional growth and highly successful IPO (Initial Public Offering). Clinigen Group was the fastest-growing UK-based private company in the 2011 Sunday Times Virgin Fast Track 100 and the only company in the pharmaceutical sector to float on the London Stock Exchange in five years. 

The IPO valued the company at £135 million and raised £10 million, which Clinigen will use to support the acquisition of rights to new products, invest in IT systems and provide general working capital. 

Peter George, chief executive of Clinigen Group, said: “We are delighted to win this award given the high calibre of entries. It’s great to see recognition of our strong international growth and organic development in a challenging economic climate, culminating in our listing on the London Stock Exchange in September. It’s fantastic to have our achievements recognised by the Bionow judging panel.” 

About Clinigen 

Clinigen is a specialty global pharmaceutical products and services business headquartered in the UK, with offices in the US and Japan. The Group has two operating divisions: services and specialty pharmaceuticals. The services division comprises Clinical Trials Supply (Clinigen CTS), which sources commercial medicinal products for use exclusively in clinical studies, including comparator trials, and Global Access Programs (Clinigen GAP), which enables patient access to unlicensed, licensed or end-­of-lifecycle products on a named basis. The specialty pharmaceuticals division focuses on acquiring and in-licensing specialist, hospital-only medicines worldwide and commercializing them within niche markets. The lead product is the anti-infective, Foscavir®, acquired from AstraZeneca in 2010. The Group has a blue chip client base of global pharmaceutical and biotech companies and contract research organizations (CROs). For more information, please visit 

About the Bionow Awards 

Bionow is a specialist business development and services company focused on the biomedical industry in the North of England. Since its inception in July 2011 it has acquired over 160 subscribing members. The Bionow Awards dinner, held on 29 November at the Mere Golf Resort & Spa, Mere, was attended by over 280 executives from the biomedical industry across the North of England and is a highlight of the biomedical calendar. For more information visit 

Media contact 

Pete Chan

Tudor Reilly 

Office: +44(0) 207 034 3208 
Mobile: +44(0)7725 554 632 


Back to News